deltatrials
Completed NCT02447978

Duration of Protection: GSK DTaP Vaccines

Duration of Protection Following Five Doses of GlaxoSmithKline's (GSK's) DTaP Vaccines in School Age Children

Sponsor: GlaxoSmithKline

Conditions Acellular Pertussis Diphtheria Tetanus
Interventions Infanrix Kinrix Pediarix
Updated 6 times since 2017 Last updated: Oct 29, 2015 Started: Feb 28, 2015 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

Listed as NCT02447978, this observational or N/A phase trial focuses on Acellular Pertussis and Diphtheria and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Jan 2021 — Jul 2024 [monthly]

    Completed

  4. Jun 2018 — Jan 2021 [monthly]

    Completed

  5. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NA → None

▶ Show 1 earlier version

  1. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Feb 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.